		i)	Patent and Trademark Office; U.S DEPARTMENT OF COMMER	CE	
	Substitute for form 1449A/PTO	m)·	COMPLETE IF KNOWN		
	INFORMATION DISCLOSU	RE Application Number	r 10/531,495		
	OTATEMENT DV ADDI ICA	Filing Date	April 15, 2005		
	STATEMENT BY APPLICA	First Named Invent	or Michael J. Breslin		
	28 \	Group Art Unit	To be determined		
	EB 2 1 2008 as many sheets as necessary)	Examiner Name	To be determined		
R.	Sheet 6 1 of	2 Attorney Docket Nut	mber 21231YP		
/	MADEN	· · · · · · · · · · · · · · · · · · ·			

U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.	U.S. Patent Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY		
YC		6,057,342		Fevig, et al.	05/02/2000		
YC		3,644,414		Helsey, et al.	02/22/1972		
YC		6,440,686		Sakowicz	08/27/2002		
			+-				
			_				
			-				
	<u> </u>						
		I	- 1		l		

			FORE	IGN PATENT	DOCUMENTS	
Examiner Initials*		Foreign Patent Document				Date of Publication of
	Cite No.	Office Number		Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY
		PCT	WO 03/105855		Merck & Co., Inc.	12/24/2003
		PCT	WO 93/20099		Yamanouchi Pharm. Co., Ltd.	10/14/1993
		PCT	WO 2005/019206		Merck & Co., rnc.	03/03/2005 NO
		PCT	WO 2005/019205		Morck & Co., Inc.	03/03/2005
		PCT	WO 03/186417		Merck & Co., Inc.	12/24/2003
		EPO	EP 418,845		Fujisawa Pharm. Co., Ltd.	06/30/2005
-						

<sup>\*</sup>Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generates form IDS Form (IDS Form) (IDS Form). Merek & Co., Inc., 17/12/2005

Approved for use through 7/31/2006. OMB 0651-0031 SUBSTITUTE for PTO/SB/08A (07-05). Information Disclosure Statement by Applicant Patent and Trademark Office; U.S DEPARTMENT OF COMMERCE

Sui	Substitute for form 1449B/PTO			COMPLETE IF KNOWN		
	NFORMATION	DIS	CLOSURE	Application Number	10/531,495	
C	מר יוינו אל האול אינים אינ	67 A TO	DE ICANIT	Filing Date	April 15, 2005	
5	TATEMENT BY	Y AP	PLICANI	First Named Inventor	Michael J. Breslin	
				Group Art Unit	To be determined	
	(use as many shee	ts as n	necessary)	Examiner Name	To be determined	
Sheet	2	of	2	Attorney Docket Number	21231YP	

		NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.							
YC		M. J. Breslin, et al., Database CALPUS on STN, DN:139:307756 (2003)						
		M. Bujard, et al., Tetrahedron Letters (40), pgs. 8785 - 8788 (1999)						
		M.J.S. Carpes, et al., Synlett., No. 7, pgs. 1037 - 1039 (2000)						
		C. Sonesson, et al., J. Org. Chem. 1996, Vol. 61, pg. 4756-4763						
		N. Iwasawa, et al., J. Org. Chem. 1998, Vol. 63, pg. 3164-3165						
$\bigvee$		N. Iwasawa, et al., J. Org. Chem. 1997, Vol. 62, pg. 1918-1919						
YC		R. Mison, et al., J. Chem. Research(S), 1989, 126-127						
	•	O. Yebdri; et al., Bulletin De La Societe Chimique de France, 1983, pg. 195-201 No translation						
		A. Ranjon, Bulletin De La Societe Chimique de France, 1971, pg. 2008-2072						
YC		A. Boukhari, et al., J. Cryst. Spect. Res., Vol. 19, Iss. 3, 1989, pg. 603-621						
		N. Moss, et al., J. Med. Chem., Vol 36 (20) pgs. 3005-3009 (1993)						
$\rightarrow$		M. Fraley, et al., "Kinesin spindle protein (KSP) inhibitors. Part 2: The design, synthesis, and characterization of 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP. Bioorganic & Medicinal Chemistry Letters (2006)						
YC		R. Garbaccio, et al., "Kinesin spindle protein (KSP) inhibitors. Part 3: Synthesis and evaluation of phenolic 2,4-diaryl-2,5-dihydropyrroles with reduced hERG binding and employment of a phosphate prodrug strategy for aqueous solubility. Bioorganic & Medicinal Chemistry Letters (2006)						

Examiner Signature	/Yong Chu/	Date Considered	07/13/2006